Northwire Canada EditionFriday, July 10, 2026
Northwire
ABX 51.81 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.82 +9.7% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.81 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.82 +9.7% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
Other Routine +

Datametrex AI Announces Completion Of Hilco Global Patent Portfolio Qualification Review

Datametrex AI Advances Patent Monetization with Hilco Global, but Execution Risks and Dilution Weigh on Shareholder Value

Executive Summary
  • Datametrex AI Limited’s subsidiary, Paymetrex, completed Hilco Global’s initial due diligence review of its patent portfolio.
  • The portfolio successfully qualified for advancement into a structured licensing initiative focused on SoftPOS and mobile payment technologies.
  • The company anticipates the broader licensing program may commence within approximately two months.
  • Management explicitly cautions that the initiative remains exploratory, with no assurance that licensing agreements, royalty arrangements, or commercial outcomes will materialize.
  • This announcement follows the April 2026 disclosure of the Hilco partnership and the March 2026 royalty-bearing license with AnywhereCommerce.
Material Impact
  • The announcement represents incremental procedural progress on a previously disclosed strategic partnership rather than a new, market-moving catalyst.
  • Completion of due diligence is a standard milestone in IP monetization and does not equate to revenue generation or contract execution.
  • Management’s explicit disclaimer regarding unguaranteed commercial outcomes reinforces the speculative nature of this revenue stream.
  • The stock has declined significantly from its November 2025 high, indicating the market has already priced in the partnership and subsequent developments.
  • The news is routine and positive in tone but lacks the materiality required to reverse the current downtrend or fundamentally alter the company’s financial trajectory.
DM · Price
Company Overview
  • Datametrex AI Limited operates across three primary verticals: healthcare services (Imagine Health Medical Clinics), AI-driven data centre infrastructure (Nutanix-based HCI solutions via Datametrex Korea), and payments technology IP licensing (Paymetrex).
  • The flagship project is the Paymetrex patent licensing program, which aims to monetize a portfolio of mobile payment and SoftPOS patents through structured licensing agreements and AI-driven analytics.
  • The company has pivoted from traditional IT services toward recurring revenue models, including long-term data centre contracts and royalty-bearing IP licenses.
  • Management emphasizes a "land and expand" strategy, targeting enterprise clients in South Korea and North America for infrastructure solutions while simultaneously pursuing global IP monetization.
Read the original news release →

More from Datametrex AI Limited